Novartis receives approval from the European Commission for Tabrecta for the treatment of non-small cell lung cancer
News
NICE opts to reject Acorda’s MS drug Fampyra
The MS Society responds as MS therapy Fampyra is rejected
AstraZeneca’s Eplontersen meets endpoints in critical phase 3 trial
Eplontersen significantly improved patient-reported quality of life following successful research
University of Strathclyde develops 3D breast cancer screening tool
Pre-clinical screening technology could increase cancer test numbers by 50 times
INTCR 2022 Winners Announced
The winners of the 2022 International Clinical Researcher of the Year have been announced.
RMI’s COVID-19 vaccine partnership with Acacium proves a success
The joint aim of the companies was to provide vaccines to vulnerable communities
Blood vessel breakthrough is major step towards Alzheimer’s treatment
The discovery may lead to development of drugs that halt disease progression and stop memory loss
Novartis receives vital licence for Scemblix
Therapy represents the first STAMP inhibitor for patients with chronic myeloid leukaemia
NICE recommends Eli Lilly’s breast cancer therapy
Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence
Genedrive genetic variant test for infants evaluated by NICE
The MT-RNR1 test was assessed under NICE’s diagnostics assessment programme
Nordic Bioscience and Roche strengthen collaboration
The companies will focus on the development of biomarkers for chronic diseases
Keensight Capital invests in AstraZeneca spin-out
The deal will boost CatSci’s ability to deliver best-in-class medicines to patients worldwide
Jazz and Redx in milestone inhibitor agreement
Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development
Merck and Mulliken Center collaborate for machine learning project
The three-year project will focus on molecular representations and computational tools
Spirea raises £2.4m to develop antibody drug conjugates in cancer
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
